Press Releases InMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors July 2, 2019 Read More » InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update May 15, 2019 Read More » InMed Pharmaceuticals to Report Third Quarter Fiscal 2019 Financial Results and Business Update on May 15, 2019 May 8, 2019 Read More » InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology March 18, 2019 Read More » InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate – INM-755 – for its Epidermolysis Bullosa Program March 13, 2019 Read More » InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March 19, 2019 March 12, 2019 Read More » InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board March 6, 2019 Read More » InMed Pharmaceuticals Reports Second Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update February 12, 2019 Read More » InMed Pharmaceuticals to Report Second Quarter Fiscal 2019 Financial Results and Business Update on February 12, 2019 February 5, 2019 Read More » InMed Pharmaceuticals Announces the Appointment of Dr. Sazzad Hossain, PhD, MSc, as a Member of the Scientific Advisory Board and his Retirement as Chief Scientific Officer January 11, 2019 Read More » InMed Pharmaceuticals to Present at Biotech Showcase 2019 on January 9, 2019 January 3, 2019 Read More » InMed Pharmaceuticals Receives Funding from the Government of Canada to Support Development of Novel Cannabinoid Biosynthesis Program December 4, 2018 Read More » InMed Pharmaceuticals Reports First Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update November 12, 2018 Read More » InMed Pharmaceuticals to Report First Quarter Fiscal 2019 Financial Results and Business Update on November 12, 2018 November 5, 2018 Read More » InMed Pharmaceuticals Appoints Michael Woudenberg as Vice President, Chemistry, Manufacturing, and Controls November 5, 2018 Read More » InMed Pharmaceuticals to Present at BIO Investor Forum on October 17, 2018 October 10, 2018 Read More » InMed Pharmaceuticals Signs Agreement with the National Research Council of Canada for Cannabinoid Biofermentation Process Development and Scale-Up October 3, 2018 Read More » InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids September 25, 2018 Read More » InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update September 13, 2018 Read More » InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work September 11, 2018 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update May 15, 2019 Read More »
InMed Pharmaceuticals to Report Third Quarter Fiscal 2019 Financial Results and Business Update on May 15, 2019 May 8, 2019 Read More »
InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology March 18, 2019 Read More »
InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate – INM-755 – for its Epidermolysis Bullosa Program March 13, 2019 Read More »
InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March 19, 2019 March 12, 2019 Read More »
InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board March 6, 2019 Read More »
InMed Pharmaceuticals Reports Second Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update February 12, 2019 Read More »
InMed Pharmaceuticals to Report Second Quarter Fiscal 2019 Financial Results and Business Update on February 12, 2019 February 5, 2019 Read More »
InMed Pharmaceuticals Announces the Appointment of Dr. Sazzad Hossain, PhD, MSc, as a Member of the Scientific Advisory Board and his Retirement as Chief Scientific Officer January 11, 2019 Read More »
InMed Pharmaceuticals to Present at Biotech Showcase 2019 on January 9, 2019 January 3, 2019 Read More »
InMed Pharmaceuticals Receives Funding from the Government of Canada to Support Development of Novel Cannabinoid Biosynthesis Program December 4, 2018 Read More »
InMed Pharmaceuticals Reports First Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update November 12, 2018 Read More »
InMed Pharmaceuticals to Report First Quarter Fiscal 2019 Financial Results and Business Update on November 12, 2018 November 5, 2018 Read More »
InMed Pharmaceuticals Appoints Michael Woudenberg as Vice President, Chemistry, Manufacturing, and Controls November 5, 2018 Read More »
InMed Pharmaceuticals to Present at BIO Investor Forum on October 17, 2018 October 10, 2018 Read More »
InMed Pharmaceuticals Signs Agreement with the National Research Council of Canada for Cannabinoid Biofermentation Process Development and Scale-Up October 3, 2018 Read More »
InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids September 25, 2018 Read More »
InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update September 13, 2018 Read More »
InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work September 11, 2018 Read More »